在欧洲肿瘤内科学会(ESMO)2023年免疫肿瘤学大会上公布了关于GDF-15抗体-介导的人类效应细胞迁移(GDFATHER-2)2a期试验(NCT04725474)结果,港安健康国际医疗介绍,将Visugromab(CTL-002)与nivolumab(Opdivo)联合治疗晚期非小细胞肺癌(NSCLC)和尿路上皮癌患者具有良好的抗癌活性。 港安健康科普: Visugromab是一种单克隆...
产品编号 T80863 别名CTL-002Cas号 2556646-63-8 Visugromab,作为针对GDF-15的中和IgG4单抗,展现出针对PD-1/PD-L1复发/难治性转移性实体瘤的显著疗效。 规格价格库存数量 1 mg 询价 期货 5 mg 询价 期货 大包装 & 定制 加入购物车 TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我...
Here we report initial results of the phase 2a part of the GDF-15 neutralizing antibody visugromab (CTL-002) in combination with nivolumab. Methods: At cut-off date (06-Feb-2023), a total of 79 pts with advanced/metastatic solid tumors have been enrolled and were treated with visugromab...
[1].Necchi A, et al. Neutralizing GDF-15 in muscle-invasive bladder cancer (MIBC): A neoadjuvant immunotherapy trial of visugromab (CTL-002) in combination with the anti-PD1 antibody nivolumab (NEO-GDFATHER)[J]. 2023. Visugromab物理化学性质 ...
In line with immune infiltration as a prerequisite of checkpoint-inhibitor responses GDF-15 serum levels negatively correlate with the response to anti-PD-(L)1 CPI therapy.2 3 Neutralization by clinical stage GDF-15 neutralizing antibody visugromab (CTL-002; GDFather-1/2 trial NCT04725474) ...